Advertisements

Альдактон

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Альдактон

Quick Facts

Property Description
Active ingredient Spironolactone (Спиронолактон)
Form Oral tablets, Oral suspension
Pharmacological class Potassium-sparing diuretic; Mineralocorticoid Receptor Antagonist
Common use Fluid management (edema) and blood pressure control
Origin Synthetic; Steroid lactone derivative

What Type of Medicine is Альдактон? (Classification and Composition)

Альдактон is a prescription pharmaceutical product containing the active ingredient Spironolactone (Спиронолактон), which is chemically classified as a synthetic steroid lactone derivative. This medication is defined as a Mineralocorticoid Receptor Antagonist, positioning it within the broader class of diuretics (water-removing medicines). Its mechanism involves fluid balance management. The drug is primarily supplied for systemic administration as an oral tablet, making it suitable for long-term chronic management.

How Does Spironolactone Differ from Other Diuretics? (Mechanism and Uniqueness)

The core differentiating feature of Spironolactone is its potassium-sparing mechanism. Unlike many other diuretic classes that cause significant loss of essential electrolytes, Spironolactone's action is based on competitively blocking the effects of the hormone aldosterone in the kidneys. This unique antagonism facilitates the excretion of excess sodium and water while conserving potassium, mitigating the risk of electrolyte depletion. Its action increases the excretion of sodium and water without increasing potassium excretion.

What is the General Purpose of This Type of Medication? (Core Therapeutic Intent)

The general therapeutic purpose of a Mineralocorticoid Receptor Antagonist like Spironolactone is to manage systemic fluid dynamics by counteracting fluid-retaining hormonal signals. This action reduces excess fluid volume in the body, providing relief from accumulation known as edema. A typical use scenario involves stabilizing fluid load to support cardiovascular function, which often results in an antihypertensive effect. Its core utility is centered on stabilizing fluid load when the body is retaining too much salt and water.

Regulatory References

  1. NIH: Spironolactone - Mechanism of Action and Uses
Advertisements

What side effects are possible with Альдактон?

Possible Side Effects and Safety Information

The medicine's safety profile is primarily characterized by its impact on electrolyte balance and the endocrine system, as documented in official regulatory labeling (such as the FDA and EMA SmPC).

Hyperkalemia (high potassium levels in the blood) is officially classified as a very common adverse reaction, particularly in patient groups with severe heart failure. This risk necessitates careful monitoring of serum potassium, especially upon treatment initiation or dose changes.

Key Adverse Reaction Categories

Adverse effects are documented across several physiological systems:

  • Endocrine and Reproductive System: Common effects related to the medicine's anti-androgenic action include Gynecomastia (male breast enlargement), which is linked to the duration of therapy, and menstrual irregularities or breast pain in females.
  • Gastrointestinal and Nervous System: Common effects listed include dizziness, headache, lethargy, nausea, vomiting, and gastric irritation.

Serious Adverse Reactions and Restrictions

Regulatory documents highlight the potential for serious adverse reactions, which are usually rare but clinically significant. These include severe electrolyte imbalances that can lead to fatal cardiac arrhythmias, Acute Kidney Injury, and severe skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

The medicine is formally contraindicated in patients with pre-existing Hyperkalemia, Addison's Disease, or severe Renal Impairment (kidney damage). Safety information also notes specific considerations for older adults and provides warnings against use during pregnancy and lactation.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Signs

Overdose involving Spironolactone is primarily associated with symptoms resulting from excessive electrolyte and fluid disruption. Manifestations documented in regulatory labeling may include gastrointestinal issues such as nausea and vomiting, as well as central nervous system effects like drowsiness and mental confusion. The most critical physiological findings are severe hyperkalemia (excessive potassium levels) and hyponatremia (low sodium levels), which signal a serious metabolic imbalance. An overdose event is of heightened concern in patients with pre-existing impaired renal function or severe hepatic disease, as these conditions increase the risk of severe hyperkalemia.

Severe Outcomes and Emergency Action

The life-threatening consequence formally documented in the official overdose profile is the potential for cardiac arrhythmias resulting from severe hyperkalemia. Due to this critical risk, regulatory authorities mandate that patients must seek immediate medical attention or contact emergency services if an overdose is suspected or if symptoms such as collapse, seizure, trouble breathing, or an irregular or slow heartbeat occur. Treatment management is defined as symptomatic and supportive treatment, focused on correcting the fluid and electrolyte imbalance. It is officially stated that no specific antidote is known for Spironolactone overdose, and medical monitoring, particularly continuous cardiac monitoring, is required.

Advertisements

Therapeutic Uses of Альдактон

What Spironolactone Treats: Main Uses and Benefits

Spironolactone is a prescription medication often included in treatment protocols to help manage symptoms related to fluid retention and high blood pressure. Its clinical indications include conditions such as congestive heart failure, essential hypertension (high blood pressure) for which alternative therapies may not be sufficient, edematous states associated with hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism. The medicine may help patients address symptoms like swelling and fluid buildup (edema), which may occur with heart or liver disease, and is a component in managing certain heart and fluid conditions. A common clinical scenario involves its use as an add-on therapy for severe heart failure to manage fluid retention and support management goals. By addressing excess fluid and blood pressure, spironolactone can contribute to symptom stabilization and support overall management plans for these conditions.


Quick Fact: Relief for Fluid Retention Spironolactone is a component of therapy used to help the body excrete excess water and sodium, which can assist in managing symptoms of fluid retention (edema).


Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Альдактон?

This information is based strictly on official government regulatory documents (e.g., FDA, EMA) defining the mandated population-eligibility profile for Spironolactone.

Absolute Contraindications (Must Not Use)

Use is prohibited for patients with pre-existing Hyperkalemia (high serum potassium levels), Anuria, or severe impairment of renal excretory function (severe kidney disease). The medication is also contraindicated in patients with Addison's disease and individuals with known hypersensitivity to Spironolactone. Co-administration with Eplerenone or other potassium-sparing diuretics (e.g., Amiloride or Triamterene) is formally prohibited.

Age and Conditional Eligibility

Adult use is established. Pediatric use is established for certain indications but requires specialist guidance. Older adults require special caution and frequent monitoring due to the increased likelihood of decreased kidney function. Patients with moderate renal or hepatic impairment require closer monitoring of serum electrolytes for conditional use.

Pregnancy and Lactation Status

Use during Pregnancy is generally not recommended or advised against due to potential fetal risk. Use while Breastfeeding is also not recommended, requiring a decision to discontinue the drug or discontinue nursing.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Spironolactone (Альдактон) based strictly on government regulatory documents (e.g., FDA, EMA SmPC).


Formally Documented Contraindicated Combinations

Co-administration of Spironolactone is formally prohibited with the following due to a high risk of severe hyperkalemia (dangerously high potassium levels):

  • Eplerenone
  • Other Potassium-Sparing Diuretics (e.g., Amiloride, Triamterene)

Clinically Significant Interaction Classes

The primary risk category involves agents that increase potassium levels, requiring close monitoring or dose adjustments:

  • Potassium Supplements and Salts
  • ACE Inhibitors (e.g., Lisinopril) and Angiotensin Receptor Blockers (ARBs) (e.g., Losartan)
  • Heparin and Low Molecular Weight Heparins
  • NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): Also documented to potentially reduce Spironolactone's therapeutic efficacy.

Other Documented Pharmacokinetic Considerations

Spironolactone may alter the body's handling of or interfere with tests for other medications:

  • Digoxin: Spironolactone and its metabolites can interfere with certain serum Digoxin assays and may increase Digoxin's half-life.
  • Lithium: Spironolactone reduces the renal clearance of Lithium, increasing the risk of toxicity.
  • Food: Food is officially documented to increase the overall bioavailability of Spironolactone.

Population-Specific Notes

The risk of interactions, particularly hyperkalemia, is heightened and requires caution in patients with renal impairment and the elderly, as stated in regulatory labeling.

Advertisements

Mechanism of Action

How Альдактон Works

Альдактон (Spironolactone) exerts its action by interfering with specific hormonal signaling systems. Its primary mechanism involves acting as a competitive antagonist against the Mineralocorticoid Receptor (MR). This receptor, located in the renal tubules, heart, and blood vessels, is the target for the hormone aldosterone.

By occupying the MR, Альдактон blocks aldosterone from binding and initiating its genomic cascade. This molecular interruption suppresses the transcription and synthesis of proteins, such as the Epithelial Sodium Channel (ENaC), which normally mediate sodium reabsorption and potassium excretion in the kidney's collecting duct. The resulting cellular changes lead to reduced reabsorption of sodium and water back into the bloodstream while simultaneously inhibiting the excretion of potassium.

This downstream effect modulates renal electrolyte transport and results in an increased output of dilute urine and a reduction in the total circulating fluid volume. The mechanism also limits the pro-fibrotic signaling associated with aldosterone in non-renal cardiovascular tissues.

Advertisements

Dosage and Administration Information

How to Use Альдактон

Альдактон (Spironolactone) is an oral preparation available in tablet form (strengths of 25 mg, 50 mg, and 100 mg) and as an oral suspension.

Dosing and Frequency Principles

Daily administration is typically recommended with a meal to enhance the absorption of the active ingredient. Dosing schedules vary based on the specific condition being managed. For example, the initial daily dose for essential hypertension ranges from 50 mg to 100 mg, while for severe heart failure, treatment often starts at 25 mg once daily. The dose may be adjusted (titrated) based on patient tolerance and response, a process requiring careful monitoring. Total daily doses above 100 mg are often administered in divided doses throughout the day.

Usage Duration and Special Populations

Use patterns range from short-term diagnostic cycles, such as 400 mg daily for several days to diagnose primary hyperaldosteronism, to long-term chronic management for conditions like heart failure and edema. When treating hypertension, the initial regimen is typically continued for a minimum of two weeks before determining the need for a dosage change. For pediatric patients, dosing is based on body weight, usually between 1 mg/kg and 3 mg/kg daily in divided doses. For older adults, the lowest possible dose is usually selected, with gradual and cautious titration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Альдактон

The research record for Spironolactone (Альдактон) is built primarily on large, controlled clinical trials and systematic reviews, reflecting regulatory reliance on the available evidence. This overview focuses strictly on the structure and content of those studies, describing what was evaluated, what patterns were observed, and what remains unclear.

Evidence for use in Severe Heart Failure

Research examined the use of Spironolactone in adults with symptomatic heart failure who were already receiving other existing therapies. Studies in this context were often designed as large-scale Randomized Controlled Trials (RCTs), where patient groups were observed over defined time intervals. These trials monitored critical outcomes related to the severity of the condition, including all-cause death and the frequency of needing to be admitted to the hospital due to worsening heart failure.

Findings describe patterns observed in these studies where differences in the frequency of events were reported between groups receiving the study treatment and those receiving a placebo. Research also describes measurements related to patient-reported experience and daily functioning or activity level, often assessed using specific classification systems.

Evidence for use in Resistant Hypertension

This section will outline the research base for using Spironolactone as an add-on therapy for high blood pressure that remains uncontrolled by existing multi-drug regimens. Research examined outcomes related to systolic and diastolic BP changes, both in the clinic and using 24-hour monitoring devices. Data show patterns related to measured blood pressure changes when Spironolactone was introduced into the existing drug regimen in the study populations. Some studies describe that patients more frequently achieved target BP goals.

Evidence for use in Fluid Management (Edema and Primary Hyperaldosteronism)

Spironolactone was studied for conditions characterized by systemic or functional imbalance leading to excess fluid retention (edema or ascites) due to liver cirrhosis or nephrotic syndrome. Research also examined its use in patients with confirmed primary hyperaldosteronism. Studies monitored outcomes such as measurements of ascites volume and changes in overall body weight related to fluid balance. Much of the supportive data is older and derived from studies with limited follow-up durations, typically only weeks or months.

What is Still Uncertain in the Research Record

Several uncertainties are noted in the regulatory record. Long-term effects are not fully established for all approved indications. Furthermore, evidence quality varies across studies, and findings were mixed regarding specific subgroups in certain trials, such as those with preserved heart function. Data for certain groups remain insufficient, especially regarding diverse racial and ethnic populations in major international studies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Альдактон (FAQ)

Q: How soon does Aldactone start to work after taking it?

Official product information indicates that the initial onset of action is characteristically slow. The maximal water-removing effect (diuresis) is typically observed after 48 hours or more. For conditions like high blood pressure, the full therapeutic benefit may take several weeks or even months of consistent use to become evident.


Q: Does Aldactone need to be taken every day?

Dosing is highly variable and depends entirely on the condition being treated. While regulatory documents show that daily administration is common for many uses, certain regimens may involve administration on an every-other-day basis. This determination is part of the individualized treatment plan.


Q: How long can Aldactone be taken?

The duration of treatment can vary widely according to regulatory guidelines. It ranges from short-term cycles for diagnostic purposes to long-term chronic management. For certain chronic conditions, such as severe heart failure, treatment may continue indefinitely under medical supervision.


Q: Is it true that Aldactone can affect hormones?

Yes, official documents describe the drug as possessing anti-androgenic activity. This means it can block the effects of androgens, which are male hormones like testosterone, by binding to their specific receptors in the body. This action is related to the drug's documented side effects in the endocrine system.


Q: Does Aldactone reduce the effectiveness of other medications?

Regulatory documents note several interactions that require careful monitoring. Specifically, the co-administration of this drug with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may potentially reduce the drug's own ability to lower blood pressure and manage fluid. Other medications, such as lithium and digoxin, may also be affected by the drug.


Q: Can Aldactone affect blood sugar levels?

Official drug labeling indicates that this medication may cause certain changes in metabolism. These changes can include an increase in blood sugar, a condition known as hyperglycemia. Therefore, monitoring of blood glucose levels is officially advised for patients, especially if they have pre-existing risk factors.


Q: Is there a withdrawal syndrome if Aldactone is stopped abruptly?

Abruptly stopping the medication is not advised, as it can reverse the beneficial therapeutic effects. Regulatory evidence from clinical studies shows that discontinuation, especially for severe heart failure patients, is associated with a high rate of clinical relapse and deterioration of heart function.


Q: What are the most common side effects of Aldactone?

According to official product information, the most frequently reported adverse reaction is high potassium levels in the blood (hyperkalemia). Other commonly reported effects are related to the endocrine system, such as male breast enlargement (gynecomastia) and menstrual irregularities in females. Common general effects also include headache, dizziness, and nausea.


Q: Can Aldactone cause fatigue or weakness?

Unusual tiredness (fatigue) and weakness are listed in official safety information as symptoms that may be experienced. These symptoms are documented as being associated with certain electrolyte imbalances, such as high potassium (hyperkalemia) or low sodium (hyponatremia), which can be side effects of the medication.


Q: Why is it necessary to monitor potassium levels when taking Aldactone?

Monitoring potassium levels is strictly required because the drug is potassium-sparing, meaning it can cause potassium to build up in the blood (hyperkalemia). Regulatory warnings indicate that severely elevated potassium levels can lead to serious and potentially life-threatening side effects, including dangerous cardiac arrhythmias (irregular heartbeats).


Q: Is it true that Aldactone is used to treat acne?

Official regulatory agencies list specific approved uses for this medication, which include managing high blood pressure, fluid retention (edema), and certain conditions characterized by excess aldosterone. Acne is not listed among the officially approved indications in the product labeling for the medication.


Q: How can a patient tell if Aldactone is working?

As the drug is intended to remove excess fluid, the therapeutic effect may involve changes such as an increase in urine output and a reduction in swelling or fluid accumulation (edema), depending on the medical condition being addressed.


Q: Can coffee or alcohol be consumed while taking Aldactone?

Official safety documents advise caution regarding the consumption of alcohol while taking this medication. Alcohol may increase the risk of side effects such as dizziness, lightheadedness, and fainting, particularly when standing up (orthostatic hypotension). Official safety materials focus caution primarily on alcohol consumption.


Q: Why does the leaflet mention a risk of tumors in animals?

The inclusion of this warning is a standard regulatory practice based on mandatory toxicity studies. Official documents indicate that chronic studies in rats demonstrated that the medication was associated with an increased occurrence of tumors in these animals. This finding is noted in the patient information leaflet as a required cautionary measure.


Q: What is Polycystic Ovary Syndrome (PCOS), and what does Aldactone have to do with it?

Polycystic Ovary Syndrome (PCOS) is a hormonal condition, but it is not listed among the officially approved indications for which this medication is regulated and labeled by government health agencies. The drug is officially indicated for the treatment of high blood pressure, edema, and certain conditions involving excessive aldosterone.


Q: Is it true that Aldactone causes frequent urges to urinate?

As a diuretic, the drug is designed to increase the output of urine, which is part of its therapeutic mechanism. Consequently, an increase in urination is an expected effect. Official product safety information also lists increased urinary frequency as a documented side effect.


Q: Can Aldactone interact with herbal supplements?

Official guidance notes that there is a potential for interaction with supplements. Specifically, supplements or herbal products that are known to increase potassium levels or have their own diuretic (water-removing) effect may increase the risk of side effects, such as a dangerous electrolyte imbalance.


Q: What effect does Aldactone have on the liver?

Official pharmacokinetic data describe how the body handles the medication. The drug is processed by the body, and its breakdown products (metabolites) are excreted primarily through the kidneys and, secondarily, through the bile, a substance produced by the liver. The labeling also includes warnings for use in patients with pre-existing liver impairment.


Q: Why is Aldactone included on the list of essential medicines?

The drug is considered an essential medicine due to its proven efficacy and high public health importance in managing major conditions. Official bodies recognize its established role, particularly in improving patient outcomes and reducing the risk of mortality in the management of severe heart failure.


Q: Is facial swelling associated with taking Aldactone?

Official safety information notes that swelling of the face or lips can be a sign of a rare but serious allergic reaction (angioedema) that requires immediate medical attention. Swelling of the ankles or feet is also documented as a possible sign of a different, serious side effect, such as acute kidney injury.


Q: What signs indicate potassium levels are too high when taking Aldactone?

Potential signs of very high potassium levels (hyperkalemia) are included in the regulatory warnings. These potential symptoms can include muscle weakness, unusual tiredness, or nausea. More serious indications include a slow or irregular heartbeat.

Advertisements

How should Альдактон be stored and disposed of?

Storage and Disposal Requirements for Aldactone (Spironolactone)

Aldactone tablets must be stored at controlled room temperature, which is officially defined as below 77 F (25 C), with permissible temperature excursions up to 86 F (30 C). The container must be kept tightly closed to protect the contents, and the product must be stored out of the reach of children as mandated by labeling.

Disposal

Official regulatory guidelines for unused or expired tablets advise disposal in the household trash if a drug take-back program is not readily available. This method requires mixing the medication with an undesirable substance (such as dirt or coffee grounds) and placing it into a sealed container before discarding. All identifying information on the prescription label must be obscured or removed for privacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Альдактон found in:

A-Z Index: